Cargando…

A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor

BACKGROUND: Oncogene signaling is known to deregulate cell proliferation resulting in uncontrolled growth and cellular transformation. Gene amplification and/or somatic mutations of the HER2/Neu (ErbB2) proto-oncogene occur in approximately 20% of breast cancers. A therapeutic strategy that has been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hinow, Peter, Wang, Shizhen Emily, Arteaga, Carlos L, Webb, Glenn F
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1852549/ https://www.ncbi.nlm.nih.gov/pubmed/17407594 http://dx.doi.org/10.1186/1742-4682-4-14

Ejemplares similares

The Functional Crosstalk between HER2 Tyrosine Kinase and TGF-β Signaling in Breast Cancer Malignancy
por: Wang, Shizhen Emily
Publicado: (2011)

Cytoprotective, Cytotoxic and Cytostatic Roles of Autophagy in Response to BET Inhibitors
por: Elshazly, Ahmed M., et al.
Publicado: (2023)

Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3
por: Sergina, Natalia V., et al.
Publicado: (2007)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

Comparative docking analysis of tyrosine kinase inhibitors with HER2 and HER4 receptors
por: Sonar, Priyanka, et al.
Publicado: (2022)

H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation via heregulin production and activation of HER3
por: Chakrabarty, Anindita, et al.
Publicado: (2010)

Cytostatic and cytotoxic effects of tyrphostin AG1296 on RMS cells
por: Lasota, Małgorzata, et al.
Publicado: (2012)

Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents
por: Serkova, Natalie J., et al.
Publicado: (2016)

Cytostatic and Cytotoxic Natural Products against Cancer Cell Models
por: Ling, Taotao, et al.
Publicado: (2019)

Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression
por: Anttila, Jani V., et al.
Publicado: (2019)

Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
por: Yang, Xue, et al.
Publicado: (2020)

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
por: Schlam, Ilana, et al.
Publicado: (2021)

Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
por: Singh, Desh Deepak, et al.
Publicado: (2022)

Modeling the bidirectional glutamine/ammonium conversion between cancer cells and cancer-associated fibroblasts
por: Hinow, Peter, et al.
Publicado: (2021)

Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors
por: Aveic, Sanja, et al.
Publicado: (2018)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Withania somnifera Induces Cytotoxic and Cytostatic Effects on Human T Leukemia Cells
por: Turrini, Eleonora, et al.
Publicado: (2016)

Screening of cytotoxic or cytostatic flavonoids with quantitative Fluorescent Ubiquitination-based Cell Cycle Indicator-based cell cycle assay
por: Go, Young-Hyun, et al.
Publicado: (2018)

Biased activation of the receptor tyrosine kinase HER2
por: Catapano, Claudia, et al.
Publicado: (2023)

Autophagic flux inhibition enhances cytotoxicity of the receptor tyrosine kinase inhibitor ponatinib
por: Corallo, Diana, et al.
Publicado: (2020)

Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells
por: Boonsri, Boonyakorn, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma
por: Gameiro, Andreia, et al.
Publicado: (2021)

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
por: Conlon, Neil T., et al.
Publicado: (2021)

Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition
por: Rexer, Brent N., et al.
Publicado: (2011)

Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model
por: Maj, Ewa, et al.
Publicado: (2017)

Proceedings: Studies on a nonspecific and non-cytotoxic cytostatic factor produced by macrophages.
por: LeJeune, F. J., et al.
Publicado: (1974)

Synthesis, antiviral, cytotoxic and cytostatic evaluation of N(1)-(phosphonoalkyl)uracil derivatives
por: Rygielska-Tokarska, Dorota, et al.
Publicado: (2016)

A Receptor Tyrosine Kinase Plays Separate Roles in Sensory Integration and Associative Learning in C. elegans
por: Wolfe, Glenn S., et al.
Publicado: (2019)

Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection
por: Climent, Núria, et al.
Publicado: (2019)

HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells
por: Kong, Anthony, et al.
Publicado: (2008)

Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib
por: Oliveras-Ferraros, Cristina, et al.
Publicado: (2011)

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells
por: McDermott, Martina S. J., et al.
Publicado: (2019)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

Cytotoxic, Cytostatic and HIV-1 PR Inhibitory Activities of the Soft Coral Litophyton arboreum
por: Ellithey, Mona S., et al.
Publicado: (2013)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_l7lugravsoapmg5rl642an7daf